Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028350 · ClinicalTrials.gov registry record · Phase 2
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT03028350 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT03028350, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD). AERD is a disease that involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other nonsteroidal anti-inflammatory drugs.
Interventions
- DRUG Placebo Oral Capsule
- DRUG Ifetroban Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03028350
The ClinicalTrials.gov registry entry for NCT03028350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT03028350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03028350 about?
NCT03028350 is a clinical study titled "Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)". The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD). AERD is a disease that involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other nonsteroidal anti-inflammatory ...
What is the current status of trial NCT03028350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2017-07-17. Estimated completion is 2023-04-25.
What interventions are being tested in trial NCT03028350?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Ifetroban Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT03028350?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.